Dr Agarwal's Health Care delivered exceptional financial performance in the quarter ended June 2026, with profit after tax surging 44.6% to ₹55 crore compared to the previous year. According to The Hindu BusinessLine, this significant profit growth demonstrates the company's strong operational performance and market positioning in the healthcare sector, even as the company absorbed higher greenfield investments during the quarter.
The company's revenue from operations increased 26% year-on-year to ₹614 crore in Q1 FY2026, up from the previous year's corresponding quarter. As reported by The Hindu BusinessLine, this substantial revenue growth reflects the company's expanding business operations and market demand for healthcare services. The quarter also marked the company's largest-ever quarterly expansion of new eye care centres, indicating strong growth momentum across the network.
EBITDA increased 25.2% to ₹177 crore in the June 2026 quarter, while EBITDA margin remained resilient at 28.5%. According to The Hindu BusinessLine, this margin performance indicates enhanced operational efficiency and cost management initiatives by the company. The company also reported same-store sales growth of 16%, demonstrating strong performance across existing locations.
Dr Agarwal's Health Care shares jumped 5.6% to a high of ₹521 on Wednesday following upgrades from global brokerages Jefferies and Morgan Stanley. As reported by The Hindu BusinessLine, Jefferies upgraded the stock from 'hold' to 'buy' and raised its target price to ₹600 from ₹510, citing faster ramp-up of new facilities driven by strong volume-led growth. The brokerage noted that execution and performance remained strong in the quarter ended June 30, with expansion continuing across all regions.
Dr Agarwal's Health Care shares rose 5.5% on Wednesday following the strong quarterly results announcement. According to The Hindu BusinessLine, the stock traded at ₹515.80 on the NSE after touching an intraday high of ₹520.90, compared with the previous close of ₹493.50. The positive market response reflects investor confidence in the company's operational performance and growth prospects in the healthcare sector.
